McGlone Suttner Wealth Management Inc. Makes New $33,000 Investment in Medpace Holdings, Inc. (NASDAQ:MEDP)

McGlone Suttner Wealth Management Inc. bought a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDPFree Report) during the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 107 shares of the company’s stock, valued at approximately $33,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Procyon Advisors LLC lifted its holdings in Medpace by 11.8% during the 4th quarter. Procyon Advisors LLC now owns 2,388 shares of the company’s stock worth $732,000 after buying an additional 252 shares during the period. Portside Wealth Group LLC lifted its holdings in Medpace by 14.8% during the 4th quarter. Portside Wealth Group LLC now owns 1,419 shares of the company’s stock worth $435,000 after buying an additional 183 shares during the period. Raymond James Financial Services Advisors Inc. acquired a new position in Medpace during the 4th quarter worth about $322,000. Raymond James & Associates lifted its holdings in Medpace by 15.1% during the 4th quarter. Raymond James & Associates now owns 47,009 shares of the company’s stock worth $14,410,000 after buying an additional 6,177 shares during the period. Finally, SG Americas Securities LLC lifted its holdings in Medpace by 32.1% during the 4th quarter. SG Americas Securities LLC now owns 3,323 shares of the company’s stock worth $1,019,000 after buying an additional 808 shares during the period. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Price Performance

Shares of Medpace stock opened at $404.15 on Friday. Medpace Holdings, Inc. has a one year low of $181.50 and a one year high of $419.42. The firm has a market capitalization of $12.43 billion, a price-to-earnings ratio of 45.51, a PEG ratio of 2.14 and a beta of 1.38. The business has a 50-day simple moving average of $368.62 and a 200 day simple moving average of $306.03.

Medpace (NASDAQ:MEDPGet Free Report) last issued its earnings results on Monday, February 12th. The company reported $2.46 EPS for the quarter, beating analysts’ consensus estimates of $2.22 by $0.24. Medpace had a return on equity of 63.98% and a net margin of 15.00%. The business had revenue of $498.40 million during the quarter, compared to analyst estimates of $498.72 million. During the same period in the previous year, the company posted $2.12 EPS. The firm’s revenue was up 26.5% compared to the same quarter last year. On average, sell-side analysts expect that Medpace Holdings, Inc. will post 10.53 EPS for the current year.

Analyst Ratings Changes

Several research analysts have commented on MEDP shares. UBS Group raised Medpace from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $282.00 to $452.00 in a report on Thursday, February 15th. Deutsche Bank Aktiengesellschaft began coverage on Medpace in a research note on Monday, March 18th. They issued a “hold” rating and a $395.00 price objective on the stock. Robert W. Baird boosted their price objective on Medpace from $312.00 to $408.00 and gave the company an “outperform” rating in a research note on Wednesday, February 14th. Finally, StockNews.com downgraded Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, March 23rd. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $382.00.

Read Our Latest Research Report on Medpace

Insider Activity at Medpace

In other Medpace news, major shareholder Medpace Investors, Llc sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $391.75, for a total transaction of $19,587,500.00. Following the completion of the sale, the insider now directly owns 5,539,947 shares of the company’s stock, valued at approximately $2,170,274,237.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Medpace news, CEO August J. Troendle sold 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $412.98, for a total transaction of $41,298,000.00. Following the completion of the sale, the chief executive officer now directly owns 4,833,019 shares of the company’s stock, valued at approximately $1,995,940,186.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Medpace Investors, Llc sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $391.75, for a total value of $19,587,500.00. Following the sale, the insider now directly owns 5,539,947 shares of the company’s stock, valued at $2,170,274,237.25. The disclosure for this sale can be found here. Insiders sold 189,340 shares of company stock valued at $76,651,647 in the last three months. Corporate insiders own 25.70% of the company’s stock.

Medpace Profile

(Free Report)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Further Reading

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDPFree Report).

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.